Niagen Bioscience, Inc. NAGE

Gabelli Investment Management Firm recently released its “Mini Mites Fund” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Fund benefited from a strong investment environment for global small- and micro-cap stocks in the second quarter of 2026, as AI adoption, reshoring, supply-chain reconfiguration, and strength in semiconductor, aerospace, defense, […]

LOS ANGELES, September 30, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced a Start-Up Agreement with Mass General Brigham (MGB) to begin detailed planning for what is envisioned to be the largest and most comprehensive clinical trial of Niagen (patented nicotinamide riboside or NR) to date.

LOS ANGELES, September 21, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the publication of independent preclinical research in Nature Communications led by a team at Sichuan Agricultural University identifying the CD38 enzyme as a primary driver of NAD+ decline in aging tissue, and that nicotinamide riboside (NR) restored NAD+ and improved placental, fetal, and offsprin

LOS ANGELES, September 17, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces today that its wholly owned subsidiary, NAD Pharmaceuticals Corp., has engaged Red Sky Partners, a life sciences strategic advisory firm, to support the advancement of NB4168, the Company’s small molecule investigational drug candidate, targeting rare genetic diseases and aging-related disorders. The Comp

LOS ANGELES, September 10, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s Well Summit, taking place from September 28 to 30, 2026, in New York.

LOS ANGELES, September 02, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.

LOS ANGELES, August 26, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on Wednesday, September 9, 2026, in San Francisco, CA.

LOS ANGELES, August 20, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD-boosting supplement in the United States†, is now available at GNC and Sam’s Club retail locations and online at www.gnc.com and www.samsclub.com.

LOS ANGELES, August 12, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the Midwest IDEAS Investor Conference on Thursday, August 27, 2026, at The InterContinental Chicago in Chicago, IL.

In early August 2026, Niagen Bioscience Inc. reported slightly lower quarterly sales and net income year on year, while also expanding access to its Tru Niagen® healthy‑aging NAD+ supplement via Walmart.com, initially offering 300 mg bottles in 30‑ and 90‑count formats. A new peer‑reviewed analysis in Aging Cell linked Niagen’s nicotinamide riboside supplementation to reduced muscle epigenetic age acceleration, adding scientific depth to its healthy‑aging positioning just as distribution...

LOS ANGELES, August 06, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that Tru Niagen®, the number one healthy-aging NAD+ supplement in the United States†, is now available at Walmart.com.

Niagen Bioscience (NAGE) is back in focus after a new peer reviewed study reported that its Niagen nicotinamide riboside supplementation was associated with reduced muscle epigenetic age acceleration compared with exercise based protocols. See our latest analysis for Niagen Bioscience. The recent clinical findings arrive after a difficult stretch for Niagen Bioscience’s stock. The 1 day share price return has fallen 14.7% and the year to date share price return has declined 52.64%. However,...

Niagen Bioscience Inc (NAGE) reports strong TrueNiagen sales growth, China cross-border revenue exceeding full-year 2025 totals, and advances in pharmaceutical pipeline with promising PRV potential.

LOS ANGELES, August 04, 2026--Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced operational updates and financial results for the second quarter of 2026.

LOS ANGELES, August 03, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ: EVO; Frankfurt Prime Standard: EVT), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168. The work will be conducted in collaboration with NAD Pharmaceuticals Corp., N

LOS ANGELES, July 28, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® (patented nicotinamide riboside, NR) supplementation was associated with reduced muscle epigenetic age acceleration measured by the Muscle Epigenetic Age Test (MEAT) clock. In addition,

LOS ANGELES, July 27, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s 46th Annual Growth Conference, taking place from August 11 to 13, 2026, in Boston.

LOS ANGELES, July 21, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Tuesday, August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, August 4, 2026.